MXPA05008959A - Polimorfos de inhibidores de proteina cinasa de 2-indolinona sustituidos con pirrolo. - Google Patents

Polimorfos de inhibidores de proteina cinasa de 2-indolinona sustituidos con pirrolo.

Info

Publication number
MXPA05008959A
MXPA05008959A MXPA05008959A MXPA05008959A MXPA05008959A MX PA05008959 A MXPA05008959 A MX PA05008959A MX PA05008959 A MXPA05008959 A MX PA05008959A MX PA05008959 A MXPA05008959 A MX PA05008959A MX PA05008959 A MXPA05008959 A MX PA05008959A
Authority
MX
Mexico
Prior art keywords
polymorphs
protein kinase
kinase inhibitors
pyrrole substituted
pyrrole
Prior art date
Application number
MXPA05008959A
Other languages
English (en)
Inventor
Tom Thamann
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of MXPA05008959A publication Critical patent/MXPA05008959A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invencion se refiere a polimorfos del compuesto 2-indolinona sustituido con 3-pirrol (2-pirrolidin -1-il -etil)- amida del acido 5-(5- fluoro-2- oxo-1, 2-dihidro -indol- 3-ildenmetil)-2, 4-dimetil- 1H-pirrol-3 -carboxilico.
MXPA05008959A 2003-02-24 2004-02-23 Polimorfos de inhibidores de proteina cinasa de 2-indolinona sustituidos con pirrolo. MXPA05008959A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44886303P 2003-02-24 2003-02-24
US10/776,337 US7452913B2 (en) 2003-02-24 2004-02-12 Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors
PCT/US2004/005281 WO2004076410A2 (en) 2003-02-24 2004-02-23 Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors

Publications (1)

Publication Number Publication Date
MXPA05008959A true MXPA05008959A (es) 2005-11-04

Family

ID=32930498

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05008959A MXPA05008959A (es) 2003-02-24 2004-02-23 Polimorfos de inhibidores de proteina cinasa de 2-indolinona sustituidos con pirrolo.

Country Status (15)

Country Link
US (2) US7452913B2 (es)
EP (2) EP1599200A4 (es)
JP (1) JP2006518755A (es)
KR (1) KR20050107588A (es)
AU (1) AU2004215407C1 (es)
BR (1) BRPI0407795A (es)
CA (1) CA2516900A1 (es)
HK (1) HK1086486A1 (es)
MX (1) MXPA05008959A (es)
NO (1) NO20054071L (es)
NZ (1) NZ541720A (es)
PL (1) PL378570A1 (es)
RU (1) RU2335502C2 (es)
WO (1) WO2004076410A2 (es)
ZA (1) ZA200506370B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7452913B2 (en) * 2003-02-24 2008-11-18 Pharmacia & Upjohn Company Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors
NZ566033A (en) * 2005-09-19 2011-04-29 Pfizer Prod Inc Solid salt forms of a pyrrole substituted 2-indolinone
TWI387019B (zh) * 2007-08-02 2013-02-21 Advanced Semiconductor Eng 在基材上形成穿導孔之方法
WO2013022801A1 (en) 2011-08-05 2013-02-14 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
CN102858739A (zh) 2010-03-10 2013-01-02 斯索恩有限公司 酰胺化吡咯甲酸酯化合物的方法
CA2818612C (en) 2010-11-19 2020-12-29 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
US9968603B2 (en) 2013-03-14 2018-05-15 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
MY182793A (en) 2014-08-08 2021-02-05 Forsight Vision4 Inc Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096757A (en) * 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
AU784266B2 (en) * 1999-12-22 2006-03-02 Sugen, Inc. Indolinone derivatives for modulation of c-kit tyrosine kinase
US6339100B1 (en) * 1999-12-29 2002-01-15 The Trustees Of Columbia University In The City Of New York Methods for inhibiting mastocytosis
ES2290117T3 (es) * 2000-02-15 2008-02-16 Sugen, Inc. Inhibidores de proteina quinasa 2-indolina sustituida con pirrol.
MY128449A (en) * 2000-05-24 2007-02-28 Sugen Inc Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
WO2002081466A1 (en) 2001-04-09 2002-10-17 Sugen, Inc. Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
TWI259081B (en) * 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
AU2003216282A1 (en) * 2002-02-15 2003-09-09 Pharmacia And Upjohn Company Llc Process for preparing indolinone derivatives
US7452913B2 (en) * 2003-02-24 2008-11-18 Pharmacia & Upjohn Company Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors

Also Published As

Publication number Publication date
PL378570A1 (pl) 2006-05-02
EP2258699A1 (en) 2010-12-08
NZ541720A (en) 2009-02-28
AU2004215407C1 (en) 2009-07-09
CA2516900A1 (en) 2004-09-10
EP1599200A2 (en) 2005-11-30
US20090048327A1 (en) 2009-02-19
NO20054071D0 (no) 2005-09-01
RU2005129743A (ru) 2006-02-10
EP1599200A4 (en) 2007-02-07
BRPI0407795A (pt) 2006-02-14
ZA200506370B (en) 2006-12-27
WO2004076410A8 (en) 2005-10-20
WO2004076410A3 (en) 2005-03-03
US7452913B2 (en) 2008-11-18
KR20050107588A (ko) 2005-11-14
NO20054071L (no) 2005-10-13
AU2004215407A1 (en) 2004-09-10
HK1086486A1 (en) 2006-09-22
JP2006518755A (ja) 2006-08-17
US20040259929A1 (en) 2004-12-23
WO2004076410A2 (en) 2004-09-10
RU2335502C2 (ru) 2008-10-10

Similar Documents

Publication Publication Date Title
EA200400183A1 (ru) Кристаллы, содержащие соль n-[2-(диэтиламино)этил]-5-[(5-фторо-2-оксо-1,2-дигидро-3h-индол-3-илиден)метил]-2,4-диметил-1h-пиррол-3-карбоксамида с яблочной кислотой, способы их получения и их композиции
NO20054071L (no) Polymorfer av pyrrol substituerte 2-indolinon protein kinase inhibitorer.
WO2006004884A3 (en) Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
BR0113931A (pt) Compostos heterocìclicos ligantes receptores de quimiocinas
MX2009006481A (es) Derivados de imidazol 1-sustituidos, y su uso como inhibidores de la sintasa de aldosterona.
SG170772A1 (en) Salts of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl- phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
NL1029799A1 (nl) Enantiomeer zuivere aminoheteroarylverbindingen als proteïnekinaseremmers.
MX2010009416A (es) Compuestos heterociclicos como inhibidores de cxcr2.
IN2014DN06567A (es)
NO20075809L (no) DNA-PK inhibitorer
WO2006050109A3 (en) Novel kinase inhibitors
EA200700699A1 (ru) Ингибиторы взаимодействия между mdm2 и p53
PT1713801E (pt) Processo para a preparação de 1-(2s,3s)-2-benzidril-n-(5- -terc-butil-2-metoxibenzil)-quinuclidina-3-amina
DE602005011784D1 (de) Pyrazoloä4,3-düpyrimidine
TW200833660A (en) Synthesis of pyrrolidine compounds
WO2007013096A8 (en) Improved process for the preparation of 2r, 3s-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1h-1,2,4-triazol-1-yl) butan-2-ol (voriconazole)
MXPA05013149A (es) Derivados de imidazol como antagonistas del receptor de glutamato.
UA107336C2 (ru) Синтез и солевые формы (r)-5-((e)-2-пирролидин-3-илвинил) пиримидина
GB0327323D0 (en) Novel pharmaceuticals
IL210141A0 (en) Pharmaceutical composition comprising n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1 h-pyrrole-3-carboxamide
TW200505853A (en) Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors
TW200745093A (en) Solid salt forms of a pyrrole substituted 2-indolinone
TN2009000147A1 (en) Crystal modifications -3-(1h-indol-3-yl)-4-[2-(4-methyl-piperazin-1-yl)-quinazolin-4-yl]-pyrrole-2,5-d ione
UA95604C2 (ru) Способ регулирования фармакокинетического и/или фармакодинамического свойства соединения
DOP2004000830A (es) Polimorfos de inhibidores de proteina quinasa de 2-indolina sustituida con pirrol

Legal Events

Date Code Title Description
FG Grant or registration